This antibody detects endogenous levels of Alpha-Synuclein only when phosphorylated at Tyrosine 136.
Aufreinigung
Immunoaffinity Chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
Immunogen
Peptide Sequence around the phosphorylation site of Tyr136 (Q-D-Yp-E-P) derived from Human Alpha-Synuclein
Western Blot: 1/500approx. 1/1000. Immunofluorescence: 1/100approx. 1/200. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Konzentration
1.0 mg/mL
Buffer
PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.02 % Sodium Azide and 50 % Glycerol.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Alpha Synuclein is implicated in the regulation of dopamine release and transport. It is a soluble protein, expressed principally in the brain but also expressed in low concentrations in all tissues examined (except liver). In the nervous system, alpha Synuclein is primarily located at presynaptic terminals and is found membrane bound in dopaminergic neurons. It can form filamentous aggregates that are the major non amyloid component of intracellular inclusions in several neurodegenerative diseases (synucleinopathies), including Parkinson's Disease. Alpha Synuclein induces fibrillization of microtubule associated protein tau and reduces neuronal responsiveness to various apoptotic stimuli, leading to a decreased caspase 3 activation. Alpha synuclein is a protein phosphorylated predominantly on serine residues.Synonyms: NACP, Non-A beta component of AD amyloid, Non-A4 component of amyloid precursor, PARK1